Vapreotide: Mechanism, Dosing & Research Data

Vapreotide is a synthetic octapeptide somatostatin analog developed for acute management of esophageal variceal bleeding in portal hypertension. Like octreotide and lanreotide, it acts on somatostatin receptors to reduce splanchnic blood flow and portal pressure, but vapreotide has unique receptor subtype selectivity and is specifically indicated for the acute variceal hemorrhage setting.

Mechanism of Action

SSTR2 activation in splanchnic vasculature causes vasoconstriction of mesenteric arterioles, reducing portal vein blood flow and portal pressure by 15-25%
Inhibits glucagon secretion from alpha cells, removing glucagon-mediated splanchnic vasodilation that contributes to portal hypertension
Reduces gastric acid secretion and motility, minimizing secondary effects in variceal bleeding patients
SSTR2 on pituitary blocks GH release; not therapeutically relevant in variceal bleeding setting but a pharmacological signature of somatostatin analogs
Distinct from octreotide: vapreotide hits SSTR1 more potently; potential advantage in some somatostatin-expressing tumors

Research Findings

Vapreotide vs placebo in acute variceal bleeding: significantly higher initial hemostasis rate (66% vs 50%) in multicenter RCT
Combined vapreotide + endoscopic sclerotherapy vs endoscopy alone: 5-day control rate 95% vs 67% in severe variceal hemorrhage
Non-inferior to terlipressin in portal pressure reduction during acute variceal bleeding in hemodynamic studies
Vapreotide approved in France for esophageal variceal bleeding; not widely available in USA where octreotide is standard
GI neuroendocrine tumor imaging: vapreotide radioisotope conjugates under investigation for SSTR-expressing tumors

Research Protocols

Acute variceal bleeding: 50 mcg IV bolus, then 50 mcg/hour IV infusion for 5 days (or until bleeding controlled)
Portal pressure measurement: 50 mcg IV bolus in HVPG (hepatic venous pressure gradient) studies; measure pressure at 30 and 60 minutes
In vitro SSTR binding: vapreotide at 0.1-100 nM against 125I-somatostatin-14 at SSTR1-5 expressed in CHO cells
NET tumor imaging: 111In-vapreotide scintigraphy at 5 mcg radiolabeled peptide IV; scan at 24 and 48 hours

Interactions

Octreotide: same class, different selectivity profile; both reduce portal pressure but through overlapping SSTR2 activation
Beta-blockers (propranolol, carvedilol): additive portal pressure reduction in prophylaxis of variceal bleeding
Insulin: vapreotide inhibits insulin release via SSTR2 on beta cells; monitor glucose in diabetic patients

Safety Profile

Generally well tolerated. GI side effects (nausea, abdominal cramping, diarrhea) in 10-20% of patients. Hyperglycemia in diabetics due to glucagon/insulin suppression. Bradycardia possible. Less hypoglycemia than vasopressin/terlipressin. Approved in France and some EU countries; used off-label elsewhere.